A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

Part of paid clinical trials in Tempe, Arizona.

Sponsor
Novo Nordisk A/S
Study ID
NCT07184632
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • NNC0662-0419 — DRUG
    NNC0662-0419 will be administered subcutaneously.
  • Placebo — DRUG
    Placebo matched to NNC0662-0419 will be administered subcutaneously.

Study Details

This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with overweight or obesity. There are 2 study treatments in this study, participants will get either NNC0662-0419, the treatment being tested or placebo, a treatment that has no active medicine in it. NNC0662-0419 is a new medicine which cannot be pre-scribed by doctors but has previously been tested in humans.

Key Dates

Start date
Oct 1, 2025
Status verified
May 2026
Primary completion
Dec 14, 2026
Completion
Dec 14, 2026

Study Design

Enrollment
224 participants (actual)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC0662-0419
    Participants will be randomized to receive NNC0662-0419 subcutaneously (s.c.). The study will be conducted in 3 parts. Part A: Multiple ascending dose (MAD), Part B: Dose range finding (DFR) and Part C (2-week escalation).
  • Placebo Comparator: Placebo
    Participant will be randomized to receive placebo in: The study will be conducted in 3 parts. Part A: Multiple ascending dose (MAD), Part B: Dose range finding (DFR) and Part C (2-week escalation).

Primary Outcome Measure

Part A: Number of treatment-emergent adverse events (TEAE) [ Time Frame: From baseline (week 0) to end of study (up to week 44) ]

Locations (2)

FacilityCityStateZIPSite coordinators
Celerion, PhoenixTempeArizona85283-
Celerion, LincolnLincolnNebraska68502-

Find similar trials in Tempe, AZ

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Celerion, Phoenix· Tempe, AZCelerion, Lincoln· Lincoln, NE

Related Studies